A stock-for-stock acquisition, supported by a $200M PIPE, creates a combined company advancing a differentiated BTK inhibitor pipeline for immune and CNS diseases. The deal targets large, underserved markets with parallel clinical programs and a cash runway into H2 2029.Original document: Processa…
The acquisition adds a differentiated BTK inhibitor to the pipeline, enabling parallel development in food allergy, CSU, and MS, funded by $200M in new financing. Phase II studies are set to begin in 2026, targeting large unmet needs with a once-daily oral therapy.Based on Processa Pharmaceuticals…
Processa acquires Vidya in a stock-for-stock deal, adding a differentiated BTK inhibitor and securing $200M in financing to fund parallel phase II studies in food allergy, CSU, and MS, with data expected in 2027–2028. The deal targets large unmet needs and multi-billion dollar markets.Based on Proc…
Processa appointed Sheila Gujrathi to its board of directors, effective July 28, 2026, following the First Effective Time under the Merger Agreement.Original SEC Filing: Processa Pharmaceuticals, Inc. [ PCSA ] - 8-K - Jul. 29, 2026This is an AI-powered summary. It may contain inaccuracies. Consider…
Processa Pharmaceuticals closed its merger with Vidya Therapeutics on July 28, issuing common and Series A preferred shares to Vidya holders and targeting a tax-free reorganization. Assuming preferred conversion, Vidya holders will own about 97% pre-PIPE; a $200.0 million PIPE of Series A preferred…
VERO BEACH, FL, July 29, 2026 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Processa) NASDAQ:PCSA today announced it has acquired Vidya Therapeutics, Inc. (Vidya), a clinical-stage biotechnology company developing VT-7208, a Bruton's tyrosine kinase (BTK) inhibitor therapy for immune-mediated…
